MedTrace Logo

Side Effects of Antipsychotic Medications

NCT00363181 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 76

Last updated 2021-03-22

No results posted yet for this study

Summary

Medications like olanzapine have been associated with the development of weight gain and diabetes in some patients. It is not known if the increased risk of developing diabetes is a direct effect on insulin or simply related to weight gain.

We hope to learn in this study whether or not olanzapine directly slows down insulin secretion from the pancreas, thereby increasing the risk of developing diabetes.

Conditions

  • Insulin Resistance
  • Metabolic Syndrome X
  • Schizophrenia and Disorders With Psychotic Features
  • Mood Disorders
  • Psychotic Disorders

Sponsors & Collaborators

Principal Investigators

  • Steven E Lindley, MD, PhD · Stanford School of Medicine / VA Palo Alto

  • Gerald M Reaven, MD · Stanford School of Medicine

Eligibility

Min Age
30 Years
Max Age
66 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-04-30
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00363181 on ClinicalTrials.gov